
- /
- Supported exchanges
- / US
- / QNCX.NASDAQ
Quince Therapeutics, Inc. (QNCX NASDAQ) stock market data APIs
Quince Therapeutics, Inc. Financial Data Overview
Quince Therapeutics, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells, as well as consists of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising kit medical devices, syringe kit, and process solutions. The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. The company was incorporated in 2012 and is headquartered in South San Francisco, California.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Quince Therapeutics, Inc. data using free add-ons & libraries
Get Quince Therapeutics, Inc. Fundamental Data
Quince Therapeutics, Inc. Fundamental data includes:
- Net Revenue:
- EBITDA: -37 753 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-12
- EPS/Forecast: -0.23
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Quince Therapeutics, Inc. News

Quince Therapeutics announces pricing of up to $22M private placement; shares up 22%
* Quince Therapeutics (NASDAQ:QNCX [https://seekingalpha.com/symbol/QNCX]) announces a private placement expected to generate $11.5M in upfront proceeds. * The deal includes common stock (or pre-f...


Oppenheimer Predicts Up to ~840% Surge for These 2 ‘Strong Buy’ Stocks
Wall Street wrapped up the week with a bang, as a solid jobs report and a possible thaw in US-China trade tensions gave investors plenty to cheer about. Protect Your Portfolio Against Market Uncertai...

Quince Therapeutics to Present at Canaccord Genuity 42nd Annual Growth Conference on August 11, 2022
SOUTH SAN FRANCISCO, Calif., August 04, 2022--(BUSINESS WIRE)--Quince Therapeutics, Inc. (Nasdaq: QNCX), a biopharmaceutical company advancing innovative precision therapeutics targeting debilitating ...

Quince Therapeutics Details Strategic Growth Plan with Launch of New Corporate Name
Strategic focus centered on advancing innovative precision therapeutics for debilitating and rare diseases Highly differentiated bone-targeting drug platform and lead precision bone growth molecule N...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.